Trimix injection is a compounded mix of three drugs (papaverine, phentolamine and alprostadil) injected into the shaft of the penis to produce an erection when pills fall short. In one five-year program of 1,412 men, 89% of trimix users were able to have intercourse.1 Alprostadil on its own (Caverject, Edex) is FDA-approved for erectile dysfunction, while compounded drugs are not FDA-approved.2-4 Your prescriber sets the dose in the office and watches for priapism, an erection that lasts too long.
What Trimix Contains and How Each Drug Works
Trimix combines one smooth muscle relaxant with two blood vessel dilators. A double-blind study described papaverine as the smooth muscle relaxant and phentolamine and prostaglandin E1 as the vasodilating agents commonly used for injection therapy.5 Prostaglandin E1 is the same molecule as alprostadil.7 The study's rationale was to pair the relaxant with one or both dilators.5
The alprostadil label explains the end result. Alprostadil relaxes the smooth muscle inside the erectile tissue and widens the cavernosal arteries by raising a signaling molecule called cyclic AMP. The erectile spaces then fill with blood, and the outflow veins are compressed against the outer sheath of the penis. The label calls this the corporal veno-occlusive mechanism.2
The proportion of each drug in your mix is a prescribing decision, and your prescriber should be able to tell you what is in the vial and why.
Who Trimix Fits
A systematic review of injectables described them as a tool for men who cannot tolerate or do not respond to oral therapies.6 If you have not yet tried a PDE5 inhibitor such as sildenafil or tadalafil, that conversation usually comes first, and the sildenafil vs tadalafil page compares those two pills.
Response differs by cause. In the five-year program, response rates were lower in men with diabetes and in men who had pelvic radiation.1 If you have diabetes, the diabetes and erectile dysfunction page explains why blood sugar and nerve health matter for erections.
The Caverject label lists who should not use alprostadil injections. One group is men with conditions that predispose them to priapism, such as sickle cell anemia or trait, multiple myeloma or leukemia. The label also excludes men with penile fibrosis, angulation or Peyronie's disease, and men with penile implants.2 If any of those apply to you, your prescriber will look at other options. The label also states that treatable medical causes of erectile dysfunction should be diagnosed and treated before therapy starts.2 The erectile dysfunction causes page walks through that workup, so your evaluation can start there.
If you are comparing injections with shockwave therapy or platelet-rich plasma, see shockwave, the P-shot and trimix.
What the Evidence Reports for Trimix
A large outcome record for trimix comes from a tertiary sexual medicine clinic that followed its injection program for five years. Of 1,412 men with complete data, most used trimix, and 89% of trimix users were capable of having intercourse.1 The recorded priapism rate was 0.5%.1
That same program reported high discontinuation by the third year. Many men who had prostate surgery stopped because their natural or pill-assisted erections recovered.1 Stopping can therefore be a good outcome, and your prescriber can tell you whether recovered erections or a problem with the injections is behind a decision to stop.
Across injectable agents, a systematic review reported clinical efficacy in 54% to 100% of patients. Early discontinuation was 38% or lower, and adverse events occurred in 26% or fewer.6 About 65% of men felt anxiety about the first injection, and that anxiety could stay high for 4 months.6 If you feel that way, it is common, and it is worth saying out loud at your first visit.
A 2013 standard operating procedures review graded the evidence. It rated alprostadil injection alone at level 1 and the bimix and trimix combination mixtures at level 2.7 Alprostadil alone has the stronger trial base. Trimix rests mainly on clinical programs and smaller studies. Your prescriber weighs that difference against how you respond and what you tolerate.
FDA Status of Trimix and Alprostadil
Among the three drugs in trimix, alprostadil is the one sold as an FDA-approved injection for erectile dysfunction.2,3,6 Caverject is indicated for the treatment of erectile dysfunction and as an adjunct in its diagnosis.2 Edex is indicated for erectile dysfunction of neurogenic, vasculogenic, psychogenic or mixed cause.3
Trimix itself is prepared by a compounding pharmacy. The FDA states that compounded drugs are not FDA-approved, which means the FDA does not verify their safety, effectiveness or quality before they are marketed.4 The Caverject label adds that combinations of Caverject with other injected vasoactive drugs have not been systematically studied and are not recommended.2
A global review of injectables found that approval of injection agents is mainly limited to alprostadil and that combination formulas vary and should be standardized.6 When your prescriber recommends trimix over an approved alprostadil product, you can ask for the reason, the pharmacy that compounds it, and the exact formula.
Bimix and the Two-Drug Formula
Bimix is papaverine and phentolamine without alprostadil.7 In a small double-blind study of 20 men, 73% reached a full erection with the three-drug solution compared with 28% on the two-drug solution. The complication rate was similar.8
A second double-blind crossover study in 7 men found that papaverine plus prostaglandin E1 produced longer erections than papaverine plus phentolamine.5 Adding phentolamine to papaverine plus prostaglandin E1 gave no extra benefit in that study.5 Both studies are small, so they show direction more than precise size.
Penile pain is the most common reaction listed on the alprostadil label.2 If injection pain is your main problem, raise it with your prescriber, who can review the formula and weigh any change against the lower response seen with two drugs.8
Quadmix and Other Four-Drug Mixes
Four-drug compounded injections, sold under names such as Quadmix, add a fourth agent to the trimix base. One randomized study of 228 men tested atropine as that fourth agent during an in-office erection test, and adding it did not improve erectile response.11 A global review found that combination formulas vary and should be standardized.6 Your prescriber should be able to name each drug in your mix and the reason it is there. Ask for that list and the compounding pharmacy's name so both go in your chart.
Priapism and Other Side Effects of Trimix Injection
Priapism is the reason the label calls for slow titration to the lowest effective dose.2 In Caverject trials, prolonged erection (4 to 6 hours) occurred in 4% of patients and priapism (6 hours or longer) in 0.4%.2 On the Edex label, erections longer than four hours occurred in 4% of patients treated up to 24 months.3
The Caverject label tells prescribers to advise patients to seek immediate medical assistance for an erection that persists longer than 4 hours.2 The American Urological Association (AUA) and the Sexual Medicine Society of North America (SMSNA) call acute ischemic priapism a medical emergency that may lead to scarring of the erectile tissue and later erectile dysfunction.10 If an erection after an injection reaches the four-hour mark, go to an emergency department, and tell the staff which drugs you injected.
The other common effects you may notice are local. Penile pain was reported by 37% of Caverject patients, mostly mild or moderate, and 3% stopped treatment because of it.2 Penile fibrosis occurred in 3%, and the label tells prescribers to follow patients for it and stop the drug if angulation or fibrosis develops.2 Injection site bleeding may occur if you take a blood thinner such as warfarin or heparin, so your prescriber needs your full medication list.2
Training, Follow-Up and Self-Injection Errors
The first injections belong in the prescriber's office. The Caverject label directs that first injections happen in the office and that the dose be titrated to the lowest effective dose. It also requires training before home use and an office visit every 3 months while you self-inject.2
Training matters because self-injection errors are common. In a program of 1,368 men, 42% made at least one error during self-injection.9 Most were minor. Penile bruising affected 34%, and 8% had no response because of a technique error.9
Major errors, the ones that can lead to priapism, were self-titrating the dose (5%) and double injecting (4%).9 Younger age and less than 12 months of injection experience predicted major errors.9 If your response changes, call your prescriber before your next injection, and let your prescriber adjust the formula or dose.
The Opt Take on Trimix Injection
An injection treats the erection, and the cause of your erectile dysfunction is still worth finding. The Caverject label itself says treatable medical causes should be diagnosed and treated before injection therapy starts.2 Trimix is not a treatment for blood sugar, lipids or testosterone. Your labs show which of those is part of your picture.
At Opt Health, every lab we order gets read by a physician before anyone is offered a treatment. Your initial panel covers 55+ biomarkers, including hormones, inflammation and cardiovascular risk, followed by a 1:1 review with an Opt Health physician. If your plan includes a prescription, it ships from our pharmacy to your door.
Full labs and a physician consultation repeat every 3 to 4 months. Your physician compares those results with your baseline, asks how your treatment is working, and adjusts the plan on what changed.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Trimix is used to treat erectile dysfunction, most often when oral medicines do not work or cannot be used.6 It is injected into the erectile tissue of the penis. Your prescriber decides whether it fits your cause and health history.
Papaverine relaxes smooth muscle, and phentolamine and alprostadil widen blood vessels.5 Alprostadil raises cyclic AMP in the erectile tissue, which lets blood fill the penis and traps it there.2 A systematic review described injections as an option for men who do not respond to oral therapies, so your prescriber may suggest it after a pill falls short.6
In a five-year clinic program, 89% of trimix users were able to have intercourse.1 Across injectable drugs, a systematic review reported efficacy in 54% to 100% of patients.6 Response was lower in men with diabetes or prior pelvic radiation, so your own odds depend on your cause.1
Pain is the most common reaction on the alprostadil label. With alprostadil alone, 37% of patients reported penile pain, mostly mild or moderate, and 3% stopped because of it.2 About 65% of men feel anxious about the first injection.6 Tell your prescriber about pain, because the formula can be reviewed.
Scarring can happen. Penile fibrosis occurred in 3% of patients in Caverject trials, and the label tells prescribers to follow patients and stop the drug if fibrosis or curvature develops.2 Priapism that is not treated quickly may also cause scarring.10 Regular follow-up visits are how your prescriber catches it early.
No. Trimix is a compounded product, and the FDA states that compounded drugs are not FDA-approved.4 Alprostadil alone is FDA-approved as Caverject and Edex.2,3 If you are offered trimix, ask your prescriber why a mix fits you better than an approved product.
Before injection therapy starts, the cause of your erectile dysfunction is worth knowing. An Opt Health membership pairs a 55+ biomarker panel with a 1:1 physician review, then repeats labs and a physician consultation every 3 to 4 months.
References
- Coombs PG et al. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012;110(11):1787-91. https://pubmed.ncbi.nlm.nih.gov/22564343/
- Pharmacia & Upjohn Company LLC. CAVERJECT (alprostadil) injection, US prescribing information. DailyMed. Published May 17, 2024. Accessed October 14, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a295fc1e-d82c-4f44-bc2d-a552bf594c98
- Endo USA, Inc. EDEX (alprostadil) injection, US prescribing information. DailyMed. Published July 13, 2026. Accessed October 14, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8b8ec8d-1318-43e4-a182-446e9f9579de
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. Content current as of September 16, 2025. Accessed October 14, 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Allen RP et al. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1. J Urol. 1992;148(4):1181-3. https://pubmed.ncbi.nlm.nih.gov/1404632/
- Duncan C et al. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol. 2019;37(6):1007-1014. https://pubmed.ncbi.nlm.nih.gov/30895359/
- Porst H et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130-71. https://pubmed.ncbi.nlm.nih.gov/23343170/
- Shenfeld O et al. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol. 1995;154(3):1017-9. https://pubmed.ncbi.nlm.nih.gov/7637045/
- Furtado TP et al. Delineating patient errors in an intracavernosal injection program. J Sex Med. 2024;21(6):529-532. https://pubmed.ncbi.nlm.nih.gov/38660738/
- Bivalacqua TJ et al. Acute ischemic priapism: an AUA/SMSNA guideline. J Urol. 2021;206(5):1114-1121. https://pubmed.ncbi.nlm.nih.gov/34495686/
- Sogari PR et al. Atropine role in the pharmacological erection test: study of 228 patients. J Urol. 1997;158(5):1760-3. https://pubmed.ncbi.nlm.nih.gov/9334595/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
This article is part of our guide to erectile dysfunction. See how Opt Health treats ED at the root cause.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.